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A need for improved understanding about USPSTF and other 
evidence-based recommendations
Mona Saraiya*, Vicki Benard, and Mary White
Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, Atlanta, 
GA, USA
Anderson et al. (Anderson et al., 2014) have provided valuable insights regarding the 
opinions of obstetrician and gynecologists (obgyns) from a survey conducted in 2010, when 
the Patient Protection and Affordable Care Act (as amended by the Healthcare and 
Education Reconciliation Act and referred to collectively as the Affordable Health Care Act) 
was passed (The Patient Protection Affordable Care Act, 2010). One provision of the Act is 
the requirement that new private health plans eliminate cost-sharing for a variety of 
preventive services, including those recommended by US Preventive Services Task Force 
(USPSTF) with an ‘A’ or ‘B’ rating (Koh and Sebelius, 2010). In 2009 the USPSTF released 
new breast cancer recommendations changing the recommended screening frequency from 
1–2 years to biennial screening and drawing a distinction on the overall effectiveness of 
mammography for women older and younger than 50 years of age. In 2009, the USPSTF 
concluded that the overall benefit was smaller for women 40 to 49 years old and 
recommended that these women discuss the potential harms and benefits of screening with 
their doctors before making an individualized decision. This occurred during the time period 
when the health reform legislation was being finalized. As a result, some may have 
misunderstood the revised recommendations for less frequent screening as a cost reduction 
measure under the Affordable Care Act rather than the evidence-based decision that the 
USPSTF intended it to be. Congress chose to allow for more expansive coverage than would 
have been required based on the 2009 USPSTF recommendations. As a result, when it was 
enacted in 2010 the Affordable Care Act required that annual breast cancer screenings be 
covered by new private health plans without cost-sharing to women aged 40 and older, based 
on the 2002 USPSTF recommendations USPSTF, 2002.
The USPSTF plays an increasingly important role in implementation of the Affordable Care 
Act as it will serve as the basis for coverage of key preventive health services. Anderson's 
(Anderson, et al., 2014) survey highlights several salient issues related to evidence-based 
recommendations. First, the results of this study suggest that providers did not have an 
accurate understanding of the makeup or the process of the USPSTF, which is an 
independent panel of nonfederal experts in prevention and evidence-based medicine (USPST 
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Force, 2013). As an independent panel, the USPSTF includes members from primary care 
and preventive medicine and includes the specialty of obstetrics and gynecology.
Second, the providers in the survey responded that potential cost-savings were factors that 
influence guidelines, but cost-effectiveness was not considered by the USPSTF. Instead, the 
USPSTF commissions decision analyses for some recommendations to estimate the balance 
of both clinical benefits and harms of preventive interventions. Cancer screening may be 
harmful by detecting abnormalities through screening that never progresses and more 
treatment that produces no benefit to the patient but instead may have adverse effects (Leach 
et al., 2012; Welch, 2013). Every screening test lends itself to a balanced discussion of 
benefits and harms, but it is especially important to understand in the context of 
opportunistic screening because the tendency is to screen for a cancer without an emphasis 
of the potential harms. A recent Cochrane review confirmed that most cancer screening trials 
do not even assess harms (Heleno et al., 2013). Due to the dearth of data on harms in clinical 
trials, the USPSTF often have to rely on other sources to assess harms of screening tests.
Third, respondents to this survey reported that besides breast care overall, they believed that 
the Affordable Care Act would have the biggest impact on overall practices and frequency of 
annual exams. This concern about the frequency of the annual exam has been highlighted in 
studies examining the impact of new cervical cancer screening guidelines where screening 
intervals have been lengthened to 3 to 5 years (Roland et al., 2011; Saraiya et al., 2010; 
Yabroff et al., 2009). Under the law, at least one well woman visit must be covered by new 
private health plans, thus providing an opportunity to focus on the quality (rather than the 
frequency) of the annual exam by offering many recommended clinical preventive services 
and increase the continuity of care (Gee, 2012). The Institute of Medicine report highlights 
that the well woman exam is not about conducting procedures but about focusing on 
comprehensive services, including counseling services (National Research Council, 2011). 
Gee et al. state that this means greater coordination of care between primary care clinicians 
who can provide the chronic disease care and the ob-gyn (Gee and Rosenbaum, 2012).
Finally, an important area for discussion, especially for ob-gyns, will be what may be 
included in the annual well-woman visit. The last iteration of the American College of 
Obstetricians and Gynecologists (ACOG) consensus guidelines included services that are 
not-evidence based and equated ob-gyns as primary care clinicians (ACOG, 2011). Even 
when clinical guidelines are evidence-based, primary care clinicians, including ob-gyns, 
deviate from such guidelines when recommending and overseeing cancer screening. For 
example, many ob-gyns use in office fecal occult blood testing (FOBT) to screen for 
colorectal cancer, when the USPSTF recommendation is to screen with a home FOBT 
annually (Nadel et al., 2010; Preventive, 2002). Other examples include cervical cancer 
screening intervals that are shorter than the recommended intervals (Roland et al., 2011), use 
of clinical breast exam for women younger than 40 years of age ACOG, 2012; ACOG., 2011 
and the use of pelvic examinations to screen for cancer (Henderson et al., 2012; Stormo et 
al., 2012). Greater reliance on evidence-based recommendations could be valuable when 
recommending and overseeing cancer screening services during a well-woman visit.
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